Loading…
Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter
Dofetilide may be advantageous in terminating atrial fibrillation/atrial flutter (AFl) when there are contraindications for class I drugs (left ventricular dysfunction and/or manifest myocardial ischemia) and beta blockers. In particular, its successful outcome in usually drug-resistant AFl is promi...
Saved in:
| Published in: | The American journal of cardiology 2000-04, Vol.85 (8), p.1031-1033 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c386t-49c7f53e64998a90185039f4b9567af80de9cd26dbad92e5c7d661191d06baa23 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c386t-49c7f53e64998a90185039f4b9567af80de9cd26dbad92e5c7d661191d06baa23 |
| container_end_page | 1033 |
| container_issue | 8 |
| container_start_page | 1031 |
| container_title | The American journal of cardiology |
| container_volume | 85 |
| creator | Lindeboom, Jan-Eize Kingma, J.Herre Crijns, Harry J.G.M. Dunselman, Peter H.J.M. |
| description | Dofetilide may be advantageous in terminating atrial fibrillation/atrial flutter (AFl) when there are contraindications for class I drugs (left ventricular dysfunction and/or manifest myocardial ischemia) and beta blockers. In particular, its successful outcome in usually drug-resistant AFl is promising and underscores the importance of selective class III action for terminating AFl. |
| doi_str_mv | 10.1016/S0002-9149(99)00927-3 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_230377695</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002914999009273</els_id><sourcerecordid>52959179</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-49c7f53e64998a90185039f4b9567af80de9cd26dbad92e5c7d661191d06baa23</originalsourceid><addsrcrecordid>eNqFkE1rFTEUhoMo9lr9CUqQLupibDK5ycxZiZRqCwUX1nU4kw9ImTu5JpnC_ffNdK4fu65CDs_75uQh5D1nnznj6uInY6xtgG_hHOATY9B2jXhBNrzvoOHAxUuy-YuckDc539cr51K9JiecdYoJ2W7I7sr7YNAcKE6WZvSuHGj0NEwl4YOb4pypjXUaxmAd9THRhPtgaXFpFyYsIU4LjyUFHKkPQwrjuI6Xxj_zcS418Za88jhm9-54npJf367uLq-b2x_fby6_3jZG9Ko0WzCdl8KpLUCPwHgvmQC_HUCqDn3PrANjW2UHtNA6aTqrFK-ftkwNiK04JR_X3n2Kv2eXi76Pc5rqk7oVTHSdAlkhuUImxZyT83qfwg7TQXOmF8f6ybFeBGoA_eRYi5r7cCyfh52z_6VWqRU4OwKYDY4-4WRC_scJpaRYer6smKsmHoJLOpvgJuNsSM4UbWN4ZpNHgI2ZZg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>230377695</pqid></control><display><type>article</type><title>Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter</title><source>Elsevier</source><creator>Lindeboom, Jan-Eize ; Kingma, J.Herre ; Crijns, Harry J.G.M. ; Dunselman, Peter H.J.M.</creator><creatorcontrib>Lindeboom, Jan-Eize ; Kingma, J.Herre ; Crijns, Harry J.G.M. ; Dunselman, Peter H.J.M.</creatorcontrib><description>Dofetilide may be advantageous in terminating atrial fibrillation/atrial flutter (AFl) when there are contraindications for class I drugs (left ventricular dysfunction and/or manifest myocardial ischemia) and beta blockers. In particular, its successful outcome in usually drug-resistant AFl is promising and underscores the importance of selective class III action for terminating AFl.</description><identifier>ISSN: 0002-9149</identifier><identifier>EISSN: 1879-1913</identifier><identifier>DOI: 10.1016/S0002-9149(99)00927-3</identifier><identifier>PMID: 10760352</identifier><identifier>CODEN: AJCDAG</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Anti-Arrhythmia Agents - administration & dosage ; Anti-Arrhythmia Agents - therapeutic use ; Antiarythmic agents ; Atrial Fibrillation - drug therapy ; Atrial Flutter - drug therapy ; Biological and medical sciences ; Cardiac arrhythmia ; Cardiology ; Cardiovascular system ; Clinical trials ; Dose-Response Relationship, Drug ; Double-Blind Method ; Female ; Humans ; Infusions, Intravenous ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Phenethylamines - administration & dosage ; Phenethylamines - therapeutic use ; Potassium Channel Blockers ; Safety ; Sulfonamides - administration & dosage ; Sulfonamides - therapeutic use ; Time Factors</subject><ispartof>The American journal of cardiology, 2000-04, Vol.85 (8), p.1031-1033</ispartof><rights>2000 Excerpta Medica Inc.</rights><rights>2000 INIST-CNRS</rights><rights>Copyright Elsevier Sequoia S.A. Apr 15, 2000</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-49c7f53e64998a90185039f4b9567af80de9cd26dbad92e5c7d661191d06baa23</citedby><cites>FETCH-LOGICAL-c386t-49c7f53e64998a90185039f4b9567af80de9cd26dbad92e5c7d661191d06baa23</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1366533$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10760352$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lindeboom, Jan-Eize</creatorcontrib><creatorcontrib>Kingma, J.Herre</creatorcontrib><creatorcontrib>Crijns, Harry J.G.M.</creatorcontrib><creatorcontrib>Dunselman, Peter H.J.M.</creatorcontrib><title>Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter</title><title>The American journal of cardiology</title><addtitle>Am J Cardiol</addtitle><description>Dofetilide may be advantageous in terminating atrial fibrillation/atrial flutter (AFl) when there are contraindications for class I drugs (left ventricular dysfunction and/or manifest myocardial ischemia) and beta blockers. In particular, its successful outcome in usually drug-resistant AFl is promising and underscores the importance of selective class III action for terminating AFl.</description><subject>Anti-Arrhythmia Agents - administration & dosage</subject><subject>Anti-Arrhythmia Agents - therapeutic use</subject><subject>Antiarythmic agents</subject><subject>Atrial Fibrillation - drug therapy</subject><subject>Atrial Flutter - drug therapy</subject><subject>Biological and medical sciences</subject><subject>Cardiac arrhythmia</subject><subject>Cardiology</subject><subject>Cardiovascular system</subject><subject>Clinical trials</subject><subject>Dose-Response Relationship, Drug</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Phenethylamines - administration & dosage</subject><subject>Phenethylamines - therapeutic use</subject><subject>Potassium Channel Blockers</subject><subject>Safety</subject><subject>Sulfonamides - administration & dosage</subject><subject>Sulfonamides - therapeutic use</subject><subject>Time Factors</subject><issn>0002-9149</issn><issn>1879-1913</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><recordid>eNqFkE1rFTEUhoMo9lr9CUqQLupibDK5ycxZiZRqCwUX1nU4kw9ImTu5JpnC_ffNdK4fu65CDs_75uQh5D1nnznj6uInY6xtgG_hHOATY9B2jXhBNrzvoOHAxUuy-YuckDc539cr51K9JiecdYoJ2W7I7sr7YNAcKE6WZvSuHGj0NEwl4YOb4pypjXUaxmAd9THRhPtgaXFpFyYsIU4LjyUFHKkPQwrjuI6Xxj_zcS418Za88jhm9-54npJf367uLq-b2x_fby6_3jZG9Ko0WzCdl8KpLUCPwHgvmQC_HUCqDn3PrANjW2UHtNA6aTqrFK-ftkwNiK04JR_X3n2Kv2eXi76Pc5rqk7oVTHSdAlkhuUImxZyT83qfwg7TQXOmF8f6ybFeBGoA_eRYi5r7cCyfh52z_6VWqRU4OwKYDY4-4WRC_scJpaRYer6smKsmHoJLOpvgJuNsSM4UbWN4ZpNHgI2ZZg</recordid><startdate>20000415</startdate><enddate>20000415</enddate><creator>Lindeboom, Jan-Eize</creator><creator>Kingma, J.Herre</creator><creator>Crijns, Harry J.G.M.</creator><creator>Dunselman, Peter H.J.M.</creator><general>Elsevier Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TS</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7Z</scope><scope>NAPCQ</scope><scope>P64</scope></search><sort><creationdate>20000415</creationdate><title>Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter</title><author>Lindeboom, Jan-Eize ; Kingma, J.Herre ; Crijns, Harry J.G.M. ; Dunselman, Peter H.J.M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-49c7f53e64998a90185039f4b9567af80de9cd26dbad92e5c7d661191d06baa23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Anti-Arrhythmia Agents - administration & dosage</topic><topic>Anti-Arrhythmia Agents - therapeutic use</topic><topic>Antiarythmic agents</topic><topic>Atrial Fibrillation - drug therapy</topic><topic>Atrial Flutter - drug therapy</topic><topic>Biological and medical sciences</topic><topic>Cardiac arrhythmia</topic><topic>Cardiology</topic><topic>Cardiovascular system</topic><topic>Clinical trials</topic><topic>Dose-Response Relationship, Drug</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Phenethylamines - administration & dosage</topic><topic>Phenethylamines - therapeutic use</topic><topic>Potassium Channel Blockers</topic><topic>Safety</topic><topic>Sulfonamides - administration & dosage</topic><topic>Sulfonamides - therapeutic use</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lindeboom, Jan-Eize</creatorcontrib><creatorcontrib>Kingma, J.Herre</creatorcontrib><creatorcontrib>Crijns, Harry J.G.M.</creatorcontrib><creatorcontrib>Dunselman, Peter H.J.M.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biochemistry Abstracts 1</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>The American journal of cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lindeboom, Jan-Eize</au><au>Kingma, J.Herre</au><au>Crijns, Harry J.G.M.</au><au>Dunselman, Peter H.J.M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter</atitle><jtitle>The American journal of cardiology</jtitle><addtitle>Am J Cardiol</addtitle><date>2000-04-15</date><risdate>2000</risdate><volume>85</volume><issue>8</issue><spage>1031</spage><epage>1033</epage><pages>1031-1033</pages><issn>0002-9149</issn><eissn>1879-1913</eissn><coden>AJCDAG</coden><abstract>Dofetilide may be advantageous in terminating atrial fibrillation/atrial flutter (AFl) when there are contraindications for class I drugs (left ventricular dysfunction and/or manifest myocardial ischemia) and beta blockers. In particular, its successful outcome in usually drug-resistant AFl is promising and underscores the importance of selective class III action for terminating AFl.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>10760352</pmid><doi>10.1016/S0002-9149(99)00927-3</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0002-9149 |
| ispartof | The American journal of cardiology, 2000-04, Vol.85 (8), p.1031-1033 |
| issn | 0002-9149 1879-1913 |
| language | eng |
| recordid | cdi_proquest_journals_230377695 |
| source | Elsevier |
| subjects | Anti-Arrhythmia Agents - administration & dosage Anti-Arrhythmia Agents - therapeutic use Antiarythmic agents Atrial Fibrillation - drug therapy Atrial Flutter - drug therapy Biological and medical sciences Cardiac arrhythmia Cardiology Cardiovascular system Clinical trials Dose-Response Relationship, Drug Double-Blind Method Female Humans Infusions, Intravenous Male Medical sciences Middle Aged Pharmacology. Drug treatments Phenethylamines - administration & dosage Phenethylamines - therapeutic use Potassium Channel Blockers Safety Sulfonamides - administration & dosage Sulfonamides - therapeutic use Time Factors |
| title | Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atrial flutter |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T03%3A13%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20intravenous%20dofetilide%20for%20rapid%20termination%20of%20atrial%20fibrillation%20and%20atrial%20flutter&rft.jtitle=The%20American%20journal%20of%20cardiology&rft.au=Lindeboom,%20Jan-Eize&rft.date=2000-04-15&rft.volume=85&rft.issue=8&rft.spage=1031&rft.epage=1033&rft.pages=1031-1033&rft.issn=0002-9149&rft.eissn=1879-1913&rft.coden=AJCDAG&rft_id=info:doi/10.1016/S0002-9149(99)00927-3&rft_dat=%3Cproquest_cross%3E52959179%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c386t-49c7f53e64998a90185039f4b9567af80de9cd26dbad92e5c7d661191d06baa23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=230377695&rft_id=info:pmid/10760352&rfr_iscdi=true |